(Q38664425)

5 September 2017

title

Pneumococcal conjugate vaccine use in adults (English)

1 reference

pneumococcal conjugate vaccine

5 September 2017

main subject

1 reference

Raul E Isturiz

1

1 reference

5 September 2017

Beate Schmoele-Thoma

2

1 reference

5 September 2017

Daniel A Scott

3

1 reference

5 September 2017

Luis Jodar

4

1 reference

5 September 2017

Chris Webber

5

1 reference

5 September 2017

Heather L Sings

6

1 reference

5 September 2017

Peter Paradiso

7

1 reference

5 September 2017

publication date

13 December 2015

1 reference

Expert Review of Vaccines

5 September 2017

published in

1 reference

5 September 2017

volume

15

1 reference

5 September 2017

issue

3

1 reference

5 September 2017

page(s)

279-293

1 reference

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Estimating the burden of hospitalization for pneumococcal pneumonia in a general population aged 50 years or older and implications for vaccination strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Understanding the burden of pneumococcal disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Pneumococcal infection in adults: burden of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Incidence and cost of pneumonia in medicare beneficiaries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Experiencing simulated aging improves knowledge of and attitudes toward aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Clinical and economic burden of pneumococcal disease in older US adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Healthcare utilization and cost of pneumococcal disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Severity of pneumococcal pneumonia associated with genomic bacterial load.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Medium-term survival after hospitalization with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Acute pneumonia and the cardiovascular system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Rates of pneumococcal disease in adults with chronic medical conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Correlation of opsonophagocytosis and passive protection assays using human anticapsular antibodies in an infant mouse model of bacteremia for Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. An open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Open-label trial of immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults ≥ 50 years of age in Mexico

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Efficacy of pneumococcal vaccination in adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Pneumococcal conjugate vaccine for adults: a new paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

Serotype-independent pneumococcal vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2016.1132171

10.1586/14760584.2016.1132171

21 January 2018

Identifiers

DOI

1 reference

5 September 2017

1 reference